GlobeNewsWire
28 Apr 2026, 05:00 UTC · 21w ago
Verdict
Headline takes no side. We score SANN +1.00 — strongly bullish.
+1.00strongly bullish
More positive than 99% of ticker scores this week
Which stocks this story touches
More positive than 99% of ticker scores this week
The company reported a 97% increase in total revenue, strong product adoption, and a clear path to cash flow breakeven.
More positive than 77% of ticker scores this week
The company is mentioned as a strategic partner driving the global expansion and adoption of AGAMREE in the U.S.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 76% of relationship scores this week
[mutual] Santhera has out-licensed the rights to AGAMREE to Catalyst Pharmaceuticals for North America.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
—
No price for SANN right now — the quote feed didn't answer.
SANN chart →
